PDFファイル 663.6 KB
PDFファイル 1.1 MB
PDFファイル 162.7 KB


Laboratory investigations (WP4): fasting plasma glucose, lipids, serum creatinine, serum


liver enzymes, biomarkers (for inflammation, copeptin, etc., see Table 1), urinary spot sample


for microalbuminuria and albumin/creatinine ratio. In addition, faeces samples will be


obtained for determination of secreted factors as well as a genetic screening for evaluation of


the gut bacterial content and composition (microbiota). A biobank will be established in


technical collaboration between Lund University and other partners (Region Skåne,


BBMRI.se). Assessment of leukocyte types and activation in whole blood will be performed


in representative subsets of subjects.


5. Metabolic investigation (WP5): including fasting blood sampling for plasma glucose and


serum lipids (total cholesterol: C, HDL-C, LDL-C and triglycerides, LpLA2, Lp(a), etc.), and


an oral glucose tolerance test (OGTT; 75 g glucose), with measurements at 0,30,(60) and 120


min of plasma glucose, incretins (GLP-1, GIP), insulin, C-peptide and glucagon.


6. Technical investigations (WP6): arterial stiffness (Sphygmocor ® assessment of pulse wave


velocity, augmentation index, central blood pressure), arteria carotis morphology and


function (Sekoya ® ultrasound device), 24-h ambulatory blood pressure recordings, and


central aortic pressure (24-h Arteriograph ® Central BP). We will perform screening


spirometry and evaluation of endothelial function (by EndoPat ®).Measurement of Advanced


Glycation End Products (AGE) will be conducted transdermally by use of an AGE-Reader®.


In addition, other investigations are optional and depending on funding, such as brain


magnetic resonance imaging (MRI) as well as echocardiography, and retinal artery imaging



The heart of the matter


Kathleen Armstrong


Tuesday, 11 October 2011 http://www.onmedica.com/GetResource.aspx?resourceId=a8c6a09c-2a7b-4f39-8348-6d75add792a7&width=210


Kathleen Armstrong looks at developments


 in cardiac patient monitoring that are improving


both the diagnosis and treatment of cardiovascular disease (CVD).


The market for cardiac patient monitoring devices market is


 growing, driven by unhealthy lifestyles, an ageing population,


and the consequent increase in cardiovascular disease (CVD).


But the main reason is growth in the demand for easy-to-use,


patient-friendly devices that enable rapid and


robust diagnoses of CVD, according to a recent report


from Frost & Sullivan1.


Robert Clark, general manager of Draeger UK,


says one of the major advances is the improvement in networking


 and the delivery of information.


All of its patient monitoring devices are WiFi-enabled


so patients can be monitored from wherever there is WiFi access in the trust. 


Draeger’s Infinity M300 is a telemetry device which is worn


by the patient and continues to communicate with a trust’s network


via the Infinity CentralStation wherever the patient is in the hospital.


It means the patient can continued to be monitored


when they go to the physiotherapist or for tests. 


“This gives the patient more flexibility and, because it continues


to monitor them, it can catch the episode that you want to capture,”


Clark says. At Derriford Hospital in Plymouth,


where the trust uses Draeger’s Infinity Omega solution, patients are


equipped with the telemetry device for a 24-hour assessment.


Because the information has been gathered without a break and


 is captured online, where it can be accessed by the cardiologist,


the patient no longer has to undergo a second session of monitoring


when they go to the cardiologist.


“Hospitals are now re-thinking their care processes,” Clark comments.  


Unimedic’s Arteriograph is a groundbreaking technology


that has advanced the way cardiac monitoring is undertaken.


Using a non-invasive catherisation method


with the help of a single arm cuff, the Arteriograph takes two minutes


 to measure individual cardiovascular risk and


evaluate the efficiency of applied therapy.


The device provides information on central and


peripheral blood pressure, endothelial function, arterial stiffness,


 arterial/heart age and cardiac fitness at the same time,


showing the effects of cardiovascular risk factors on the arteries.


Unimedic’s Arteriograph measures individual cardiovascular risk


 and evaluates the efficiency of applied therapy within two minutes


Unimedic’s Arteriograph.jpg


In mid-September the company also launched the Arteriograph 24,


an ambulatory device which will enable central blood pressure and


arterial stiffness to be monitored over a 24-hour period.


The device is the more-advanced version of


the most accurate (BHS AA validated) and best value


for money ambulatory blood pressure monitor on the market,


the TensioDay ABPM, which comes with a professional software package.


 It is an idea solution for practices wanting to comply


with the recommendations of the new NICE Hypertension Guideline


 for diagnosing high blood pressure.  


TensioDay ABPM helps practices to comply with new NICE guidelines


for diagnosing high blood pressure


TensioDay ABPM.jpg  


13 July 2011 


Draeger UK
Welch Allyn





Diurnal variation in blood pressure and arterial stiffness in CKD – the role of endothelin-1


Neeraj Dhaun,Rebecca Moorhouse, Iain M MacIntyre, Vanessa Melville,


Robert A Kimmitt, Kayleigh E Brown, Euan Kennedy, Jane Goddard, David J Webb


BHF Centre of Research Excellence, University of Edinburgh






Hypertension and arterial stiffness are important independent cardiovascular risk factors in CKD to which endothelin-1 (ET-1) contributes. Whereas loss of nocturnal blood pressure (BP) dipping in CKD is associated with disease progression there are no data on diurnal variations in arterial stiffness. We examined the diurnal variation of BP, arterial stiffness and the ET system in CKD and the effects on these of ETA receptor antagonism.






First, in a case-control study we compared 24h ambulatory BP and arterial stiffness using the TensioMed™ Arteriograph 24 ambulatory arterial stiffness monitor in 16 patients with CKD and 15 matched controls. Second, in an observational study we examined the diurnal variation in plasma and urinary ET-1 (midday and midnight) in 15 patients with CKD. Third, in a randomised double-blind, 3-way crossover study in 27 patients with CKD, we examined the effects of 6 weeks’ treatment with placebo, sitaxentan (an ETA receptor antagonist), and nifedipine on the diurnal variation of BP assessed at baseline and week 6 of each study period. This was in addition to the primary endpoints of proteinuria, BP and arterial stiffness.






There were nocturnal dips in systolic and diastolic BP (SBP, DBP) and pulse wave velocity (PWV), our measure of arterial stiffness, in 15 controls (SBP -3.2 ± 4.8%, p < 0.05; DBP -6.4 ± 6.2%, p = 0.001; PWV -5.8 ± 5.2%, p < 0.01), but not in 16 CKD patients. In 15 CKD patients, plasma ET-1 increased from 4.8 ± 1.5 at midday to 5.1 ± 1.5pg/ml at midnight (p < 0.01). Urinary ET-1 did not change. 6 weeks’ treatment with placebo and nifedipine did not affect nocturnal dips in SBP or DBP between baseline and week 6 whereas dipping was increased following 6 weeks’ sitaxentan treatment (baseline vs. week 6, SBP: -7.0 ± 6.2 vs. -11.0 ± 7.8mmHg, p < 0.05; DBP: -6.0 ± 3.6 vs. -8.3 ± 5.1mmHg, p < 0.05). There was no nocturnal dip in pulse pressure at baseline in the 3 phases of the study, whereas sitaxentan was linked to the development of a nocturnal dip in pulse pressure.






In CKD, activation of the ET system appears to contribute not only to raised BP, but also the loss of BP dipping. The clinical significance of these findings should be explored in future clinical trials.






TEL:  048-928-0168





ご研究発表の新しい診断機器のご提案 超音波機能に、動脈硬化指標診断機能、12誘導心電図機能などの組み合わせ